Cited by 678Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Shigematsu, Hisayuki, Takahashi, Takao, Nomura, Masaharu, Majmudar, Kuntal, Suzuki, Makoto, Lee, Huei, Wistuba, Ignacio I., Fong, Kwun M., Toyooka, Shinichi, Shimizu, Nobuyoshi, Fujisawa, Takehiko, Minna, John D., Gazdar, Adi F.·2005·Cancer Research

DOI 10.1158/0008-5472.can-04-4235

Open this paper in CoChat — free account

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 1.6% (11 of 671) of NSCLC and were absent in other types of cancers. Only one adenocarcinoma cell line (NCI-H1781) had a mutation. All HER2 mutations were in-frame insertions in exon 20 and target the identical corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003). In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%). Mutations in EGFR, HER2, and KRAS genes were never present together in individual tumors and cell lines. The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors. EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-4235

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · CHEST Journal · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation

Show all 28 references

Sorted by citations

Items 201–300 of 678

Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
Gower, A., Wang, Y., & Giaccone, G. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1165-y · Cited by 68
Recent advances of novel targeted therapy in non-small cell lung cancer
Katzel, J. A., Fanucchi, M. P., & Li, Z. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-2 · Cited by 70
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 69
Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor
Berge, E. M., & Doebele, R. C. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.006 · Cited by 65
Her4 and Her2/neu Tyrosine Kinase Domains Dimerize and Activate in a Reconstituted in Vitro System
Monsey, J. D., Shen, W., Schlesinger, P. H., & Bose, R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.096032 · Cited by 65
ErbBs in lung cancer
Sharma, S. V., & Settleman, J. E. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.026 · Cited by 67
From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers
Gazdar, A. F., Hirsch, F. R., & Minna, J. D. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.009 · Cited by 64
Self-citation
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Cornelissen, R., Prelaj, A., Sun, S. B., Baik, C. S., Wollner, M., Haura, E. B., Mamdani, H. M., Riess, J. W., Cappuzzo, F., Garassino, M. C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.016 · Cited by 62
Analysis of different HER ‐2 mutations in breast cancer progression and drug resistance
Sun, Z., Shi, Y., Shen, Y., Cao, L., Zhang, W., & Guan, X. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12662 · Cited by 64
Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): A case study
Pegram, M. D., & Ngo, D. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.003 · Cited by 62
Epidermal growth factor receptor expression status in lung cancer correlates with its mutation
Suzuki, M., Shigematsu, H., Hiroshima, K., Iizasa, T., Nakatani, Y., Minna, J. D., Gazdar, A. F., & Fujisawa, T. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.08.007 · Cited by 62
Self-citation
Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression
Willmore‐Payne, C., Holden, J. A., & Layfield, L. J. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.02.004 · Cited by 61
EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992
Spicer, J. F., & Rudman, S. M. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0140-y · Cited by 61
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
Doebele, R. C., Oton, A. B., Peled, N., Camidge, D. R., & Bunn, P. A. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.12.009 · Cited by 62
A review of HER2 overexpression and somatic mutations in cancers
Galogre, M. I., Rodin, D., Pyatnitskiy, M. A., Mackelprang, M., & Koman, I. E. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103997 · Cited by 60
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer
Dudek, A. Z., Leśniewski-Kmak, K., Koopmeiners, J. S., & Keshtgarpour, M. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.09.002 · Cited by 59
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
Savas, P. S., Hughes, B. G. M., & Solomon, B. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.08.52 · Cited by 59
Automated tumor analysis for molecular profiling in lung cancer
Hamilton, P. W., Wang, Y., Boyd, C., James, J. A., Loughrey, M. B., Hougton, J. P., Boyle, D. P., Kelly, P., Maxwell, P., McCleary, D. F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4391 · Cited by 58
Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors
Landau, M., & Ben‐Tal, N. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.08.001 · Cited by 58
Inherited lung cancer syndromes targeting never smokers
Yamamoto, H., Yatabe, Y., & Toyooka, S. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.01 · Cited by 56
Self-citation
Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness
Terlizzi, M., Colarusso, C., Pinto, A., & Sorrentino, R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.005 · Cited by 61
Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K. H., Cao, S., Chouitar, J., Wu, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1526 · Cited by 57
Current concepts on the molecular pathology of non-small cell lung carcinoma
Fujimoto, J., & Wistuba, I. I. (2014) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2014.06.008 · Cited by 58
Self-citation
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
Hong, L., Patel, S. A., Drusbosky, L. M., Xiong, Y., Chen, R., Geng, R., Heeke, S., Nilsson, M. B., Wu, J., Heymach, J. V., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00720-9 · Cited by 62
Lung Cancer in Never Smokers
Török, S., Hegedűs, B., László, V., Hoda, M. A., Ghanim, B., Berger, W., Klepetko, W., Döme, B., & Ostoros, G. (2011) · Future Oncology · doi:10.2217/fon.11.100 · Cited by 56
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
Tschui, J., Vassella, E., Bandi, N., Baumgartner, U., Genitsch, V., Rotzer, D., Seiler, R., Thalmann, G. N., & Fleischmann, A. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1729-4 · Cited by 55
Biomarkers of drugs targeting HER ‐family signalling in cancer
Montemurro, F., & Scaltriti, M. (2013) · The Journal of Pathology · doi:10.1002/path.4269 · Cited by 56
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
Yang, S., Wang, Y., Zhao, C., Li, X., Liu, Q., Mao, S., Liu, Y., Yu, X., Wang, W., Tian, Q., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-559 · Cited by 60
Clinical experience with gefitinib: An update
Cappuzzo, F., Finocchiaro, G., Metro, G., Bartolini, S., Magrini, E., Cancellieri, A., Trisolini, R., Castaldini, L., Tallini, G., & CRINO, L. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.008 · Cited by 54
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Hanna, N. H. (2006) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)70160-x · Cited by 53
Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
Ahn, M., Park, B.-B., Ahn, J. S., Kim, S. W., Kim, H., Lee, J. S., Kang, J., Choi, Y., SONG, H. S., Park, S. H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4608 · Cited by 50
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
Eng, J., Hsu, M., Chaft, J. E., Kris, M. G., Arcila, M. E., & Li, B. T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.030 · Cited by 52
MOCSS: Multi-omics data clustering and cancer subtyping via shared and specific representation learning
Chen, Y., Wen, Y., Xie, C., Chen, X., He, S., Bo, X., & Zhang, Z. (2023) · iScience · doi:10.1016/j.isci.2023.107378 · Cited by 51
Inherited lung cancer: a review
de Alencar, V. T. L., Formiga, M. N., & de Lima, V. C. C. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1008 · Cited by 57
Salvage Therapy for Advanced Non-Small Cell Lung Cancer: Factors Influencing Treatment Selection
Ramalingam, S. S., & Sandler, A. B. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-655 · Cited by 50
The Molecular Genetics of Lung Cancer
Shames, D. S., Sato, M., & Minna, J. D. (2008) · Lung Cancer · doi:10.1002/9780470696330.ch4 · Cited by 50
Self-citation
Aberrant Receptor Signaling and Trafficking as Mechanisms in Oncogenesis
Rusten, T. E., Haglund, K., & Stenmark, H. (2007) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v13.i1.20 · Cited by 50
Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Lorch, G., Sivaprakasam, K., Zismann, V., Perdigones, N., Contente‐Cuomo, T., Nazareno, A., Facista, S. J., Wong, S., Drenner, K., Liang, W. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1145 · Cited by 49
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Herbst, R. S., & Sandler, A. B. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0108 · Cited by 49
Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Toschi, L., & Cappuzzo, F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-211 · Cited by 48
Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu
Piechocki, M. P., Yoo, G. H., Dibbley, S. K., & Lonardo, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0765 · Cited by 48
Atomistic Insights into Regulatory Mechanisms of the HER2 Tyrosine Kinase Domain: A Molecular Dynamics Study
Telesco, S., & Radhakrishnan, R. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2008.12.3912 · Cited by 48
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
Califano, R., Abidin, A. Z., Tariq, N.-U.-A., Economopoulou, P., Metro, G., & Mountzios, G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.009 · Cited by 49
Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient
Hirotsu, Y., Nakagomi, H., Amemiya, K., Oyama, T., Inoue, M., Mochizuki, H., & Omata, M. (2016) · Medical Oncology · doi:10.1007/s12032-016-0857-2 · Cited by 47
The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-βSignaling in Breast Cancer Malignancy
Wang, S. E. (2011) · Journal of Signal Transduction · doi:10.1155/2011/804236 · Cited by 49
ERBB2 kinase domain mutation in the lung squamous cell carcinoma
Lee, J. W., Soung, Y. H., Kim, S. Y., Nam, S. W., Park, W. S., Wang, Y. P., Jo, K. H., Moon, S. W., Song, S. Y., Lee, J. Y., et al. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.05.026 · Cited by 47
Targeting ADAMS and ERBBs in lung cancer
Hynes, N. E., & Schlange, T. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.012 · Cited by 47
Identification of the Coexisting HER2 Gene Amplification and Novel Mutations in the HER2 Protein-Overexpressed Mucinous Epithelial Ovarian Cancer
Lin, W., Kuo, W., Chen, F., Lee, M., Ruan, A., Tyan, Y., Hsu, J., Chiang, H., & Han, C. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1572-z · Cited by 46
Targeted therapy for NSCLC with driver mutations
Minuti, G., D’Incecco, A., & Cappuzzo, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.827657 · Cited by 46
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators
Wang, S. E., Yu, Y., Criswell, T. L., DeBusk, L. M., Lin, P., Zent, R., Johnson, D. H., Ren, X., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.112 · Cited by 47
Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma
Matsumoto, S., Iwakawa, R., Kohno, T., Suzuki, K., Matsuno, Y., Yamamoto, S., Noguchi, M., Shimizu, E., & Yokota, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21670 · Cited by 46
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
Xu, W., Soga, S., Beebe, K. L., Lee, M.-J., Kim, Y. S., Trepel, J. B., & Neckers, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603950 · Cited by 44
Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer
Kubo, T., Kuroda, Y., Shimizu, H., Kokubu, A., Okada, N., Hosoda, F., Arai, Y., Nakamura, Y., Taniguchi, H., Yanagihara, K., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp206 · Cited by 45
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study
Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Xing, P., Zhang, S., Ai, X., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221082339 · Cited by 44
Engagement of Overexpressed Her2 with GEP100 Induces Autonomous Invasive Activities and Provides a Biomarker for Metastases of Lung Adenocarcinoma
Menju, T., Hashimoto, S., Hashimoto, A., Otsuka, Y., Handa, H., Ogawa, E., Toda, Y., Wada, H., Date, H., & Sabe, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025301 · Cited by 44
A Subset of Lung Adenocarcinomas and Atypical Adenomatous Hyperplasia–Associated Foci Are Genotypically Related
Sartori, G., Cavazza, A., Bertolini, F., Longo, L., Marchioni, A., Costantini, M., Barbieri, F., Migaldi, M., & Rossi, G. (2008) · American Journal of Clinical Pathology · doi:10.1309/thu13f3jrjvwlm30 · Cited by 44
Cancer of the Lung
Araujo, L. H., Horn, L., Merritt, R. E., Shilo, K., Xu‐Welliver, M., & Carbone, D. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00069-4 · Cited by 47
Inhibition of EGFR Signaling: All Mutations Are Not Created Equal
Gazdar, A. F., & Minna, J. D. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020377 · Cited by 43
Self-citation
Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Ivanova, E. V., Kuraguchi, M., Xu, M., Portell, A. J., Taus, L. J., Diala, I., Lalani, A. S., Choi, J., Chambers, E. S., Li, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1844 · Cited by 45
Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab
Kelly, R. J., Carter, C. A., & Giaccone, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.3126 · Cited by 42
Mutational Analyses of Multiple Oncogenic Pathways in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Schönleben, F., Allendorf, J., Qiu, W., Li, X., Ho, D. J., Ciau, N. T., Fine, R. L., Chabot, J. A., Remotti, H. E., & Su, G. H. (2008) · Pancreas · doi:10.1097/mpa.0b013e318158a4d2 · Cited by 42
Responses of Human Colorectal Tumor Cells to Treatment with the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib
Cunningham, M., Thomas, H., Fan, Z., & Modjtahedi, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1000 · Cited by 43
Targeted Therapies in Lung Cancer
Chirieac, L. R., & Đačić, S. (2010) · Surgical pathology clinics · doi:10.1016/j.path.2010.04.001 · Cited by 41
Antitumor activity of pan‐ HER inhibitors in HER 2‐positive gastric cancer
Yoshioka, T., Shien, K., Namba, K., Torigoe, H., Sato, H., Tomida, S., Yamamoto, H., Asano, H., Soh, J., Tsukuda, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13546 · Cited by 41
Self-citation
Establishment and characterization of primary lung cancer cell lines from Chinese population
Zheng, C., Sun, Y.-H., Ye, X.-L., Chen, H., & Ji, H.-B. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.214 · Cited by 41
Molecular profile of lung cancer in never smokers
Subramanian, J., & Govindan, R. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.004 · Cited by 43
A growing family: Adding mutated Erbb4 as a novel cancer target
Rudloff, U., & Samuels, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11239 · Cited by 40
A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3receptortyrosinekinasesignaling network
Telesco, S., Shih, A., Jia, F., & Radhakrishnan, R. (2011) · Molecular BioSystems · doi:10.1039/c0mb00345j · Cited by 40
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
Ninomiya, K., Hata, T., Yoshioka, H., Ohashi, K., Bessho, A., Hosokawa, S., Ishikawa, N., Yamasaki, M., Shibayama, T., Aoe, K., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.01.011 · Cited by 40
Self-citation
Acquired resistance mechanisms to afatinib in HER 2‐amplified gastric cancer cells
Yoshioka, T., Shien, K., Takeda, T., Takahashi, Y., Kurihara, E., Ogoshi, Y., Namba, K., Torigoe, H., Sato, H., Tomida, S., et al. (2019) · Cancer Science · doi:10.1111/cas.14089 · Cited by 42
Self-citation
The genomic landscape of nonsmall cell lung carcinoma in never smokers
Boeckx, B., Shahi, R. B., Smeets, D., Brakeleer, S. D., Decoster, L., Brussel, T. V., Galdermans, D., Vercauter, P., Decoster, L., Alexander, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32797 · Cited by 40
HER2: An emerging biomarker in non-breast and non-gastric cancers
Omar, N., Yan, B., & Salto‐Tellez, M. (2015) · Pathogenesis · doi:10.1016/j.pathog.2015.05.002 · Cited by 40
Establishment and Expression Profiling of New Lung Cancer Cell Lines from Chinese Smokers and Lifetime Never-Smokers
Lam, D. C.-L., Girard, L., Suen, W., Chung, L., Tin, V. P., Lam, W.-K., Minna, J. D., & Wong, M. P. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31624-5 · Cited by 40
Self-citation
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
Zer, A., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00329 · Cited by 39
MicroRNA and HER2-overexpressing Cancer
Wang, S., & Lin, R.-J. (2013) · MicroRNA · doi:10.2174/22115366113029990011 · Cited by 42
Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Guarini, C., Grassi, T., Pezzicoli, G., & Porta, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136813 · Cited by 41
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
Li, G., Wang, X., Hibshoosh, H. H., Jin, C., & Halmos, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106349 · Cited by 39
ERBB2 mutation: A promising target in non-squamous cervical cancer
Xiang, L., Jiang, W., Ye, S., He, T., Pei, X., Li, J., Chan, D. W., Ngan, H., Li, F., Tao, P., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.12.023 · Cited by 39
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going
Rosell, R., Cuello, M. A., Cecere, F. L., Santarpía, M., Reguart, N., Felip, E., & Tarón, M. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000208786.91947.eb · Cited by 39
EGFR , KRAS , BRAF , and HER ‐2 molecular status in brain metastases from 77 NSCLC patients
Villalva, C., Duranton‐Tanneur, V., Guilloteau, K., Burel‐Vandenbos, F., Wager, M., Doyen, J., Levillain, P., Fontaine, D., Blons, H., Pédeutour, F., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.82 · Cited by 38
Comprehensive genomic profiling and prognostic analysis of cervical gastric-type mucinous adenocarcinoma
Lu, S., Shi, J., Zhang, X., Kong, F., Liu, L., Dong, X., Wang, K., & Shen, D. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03080-y · Cited by 41
Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain
Sonobe, M., Manabe, T., Wada, H., & Tanaka, F. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050132 · Cited by 38
Oncogenes Come of AgePreprint
VARMUS, H. E., Pao, W. J., Politi, K. A., Podsypanina, K., & Du, Y. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.039 · Cited by 36
EGF and TGF-1 Effects on Thyroid Function
Mincione, G., Marcantonio, M. C. D., Tarantelli, C., D'inzeo, S., Nicolussi, A., Nardi, F., Donini, C. F., & Coppa, A. (2011) · Journal of Thyroid Research · doi:10.4061/2011/431718 · Cited by 37
Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I
Upadhya, A., Yadav, K. S., & Misra, A. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825377 · Cited by 38
EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy
Fu, Y.-N., Yeh, C.-L., Cheng, H.-Y. H., Yang, C.-H., Tsai, S., Huang, S.-F., & Chen, Y.-R. (2008) · Oncogene · doi:10.1038/sj.onc.1210684 · Cited by 42
Wnt/β-Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer
Rao, A. S., Kremenevskaja, N., von Wasielewski, R., Jakubcakova, V., Kant, S., Resch, J., & Brabant, G. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1381 · Cited by 37
Retracted
Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
Bu, S., Wang, R., Pan, Y., Yu, S. J., Shen, X., Li, Y., Sun, Y., & Chen, H. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5044-8 · Cited by 37
Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer
Gkolfinopoulos, S., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.28 · Cited by 37
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
Shin, J. W., Kim, S., Ha, S., Choi, B., Kim, S., Im, S., Yoon, T., & Chung, J. (2019) · Biomolecules · doi:10.3390/biom9100629 · Cited by 36
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
Kirchner, M., Kluck, K., Brandt, R., Volckmar, A., Penzel, R., Kazdal, D. N., Endris, V., Neumann, O., Seker‐Cin, H., Goldschmid, H., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100253 · Cited by 39
Differential Methylation of a Short CpG-Rich Sequence within Exon 1 of TCF21 Gene: A Promising Cancer Biomarker Assay
Shivapurkar, N., Stastny, V., Xie, Y., Prinsen, C., Frenkel, E. P., Czerniak, B. A., Thunnissen, E., Minna, J. D., & Gazdar, A. F. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2808 · Cited by 36
Self-citation
Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
Kong, X., Zhang, K., Wang, X., Yang, X. C., Li, Y., Zhai, J., Xing, Z., Qi, Y., Gao, R., Feng, X., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s194137 · Cited by 35
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics
Alaoui‐Jamali, M. A., Morand, G. B., & da Silva, S. D. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00017 · Cited by 34
Point mutations of protein kinases and individualised cancer therapy
Davies, M. A., Hennessy, B. T., & Mills, G. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.16.2243 · Cited by 34
Molecular epidemiology of cancer
Zaridze, D. G. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050064 · Cited by 34

Authors: Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., Fujisawa, T., Minna, J. D., & Gazdar, A. F.
Affiliations: Okayama University (JP)
1Hamon Center for Therapeutic Oncology Research, Departments of
Chiba University (JP)
Chung Shan Medical University (TW)
The University of Texas MD Anderson Cancer Center (US)
Prince Charles Hospital (AU)
The University of Texas Southwestern Medical Center (US)
ORCID: Majmudar, Kuntal
Suzuki, Makoto
Wistuba, Ignacio I.
Fong, Kwun M.
Toyooka, Shinichi
Minna, John D.
Gazdar, Adi F.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2005-03-01
Volume: 65
Issue: 5
Pages: 1642-1646
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-04-4235
OpenAlex: W2133867160
Cited by: 678
References: 28
Citations by year: 2026: 8 · 2025: 17 · 2024: 13 · 2023: 18 · 2022: 16 · 2021: 36 · 2020: 29 · 2019: 27 · 2018: 36 · 2017: 23 · 2016: 27 · 2015: 46 · 2014: 46 · 2013: 54 · 2012: 34
FWCI: 42.08
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute ((P50-CA70907, P50CA070907, 5U01 CA 8497102)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, lung adenocarcinoma, non-small cell lung cancer, EGFR mutation, KRAS mutation, tyrosine kinase domain, never smokers, ethnic differences in mutation frequency, lung cancer etiology, EGFR kinase inhibitors
MeSH terms: Adenocarcinoma, Aged, Aged, 80 and over, Amino Acid Sequence, Female, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasms, Glandular and Epithelial, Genes, ras, Sequence Homology, Amino Acid, Genes, erbB-2, Genes, erbB-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks